Variability in HbA1c and the risk of major clinical outcomes in type 2 diabetes with chronic kidney disease: Post hoc analysis from the CREDENCE trial

Documenti analoghi

• An overview of the CANVAS Program and CREDENCE trial: The primary outcomes and key clinical implications for those managing patients with type 2 diabetes
  di: Angela X. Chen, et al.
  Pubblicazione: (2024)
• Machine learning for prediction of chronic kidney disease progression: Validation of the Klinrisk model in the CANVAS Program and CREDENCE trial
  di: Navdeep Tangri, et al.
  Pubblicazione: (2024)
• Geographic and racial variability in kidney, cardiovascular and safety outcomes with canagliflozin: A secondary analysis of the CREDENCE randomized trial
  di: Kathryn Cardoza, et al.
  Pubblicazione: (2024)
• Availability and readiness of health facilities for chronic kidney disease, diabetes and cardiovascular disease in Ethiopia: Evidence from service provision assessment data
  di: Daniel Bekele Ketema, et al.
  Pubblicazione: (2025)
• Baseline HbA1c and dementia risk at SGLT2i initiation in type 2 diabetes
  di: Jiaqiang Zhang, et al.
  Pubblicazione: (2025)